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In most H. pylori-positive patients, gastric low-grade 
mucosa-associated lymphoid tissue (MALT) lympho-
mas regress both endoscopically and histopathologi-
cally after H. pylori eradication, but no factors that 
can be predictive of the response to the eradication 
have been definitively identified, and there is little in-
formation on how to determine the optimal observation 
period before additional treatment can be started. Here, 
clinical studies dealing with the diagnosis and treat-
ment of gastric MALT lymphomas and H. pylori pub-
lished during the last 5 years were systematically re-
viewed, and studies identifying the molecular appro-
aches involved in the pathogenesis were summarized. 
Most of the clinical studies indicate a favorable effect 
of  H. pylori eradication on the clinical outcome of   
gastric MALT lymphomas. Some studies suggest the 
necessity of additional treatment in nonresponders to 
H. pylori eradication, while others suggest the adop-
tion of a watch-and-wait strategy. The molecular char-
acteristics of MALT lymphomas could play an impor-
tant role in prognostic prediction and the selection of 
further therapeutic intervention after the eradication. 
This updated review of gastric MALT lymphomas illus-
trates the potential efficacy of H. pylori eradication in 
tumor remission, but further molecular characterization 
is necessary to establish the most suitable therapeutic 
strategy for patients who do not respond to eradication. 
(Gut and Liver 2009;3:81-87)
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INTRODUCTION
  Helicobacter pylori ( H. pylori) is a gram-negative, micro-
aerobic rod that lives in the gastric mucous layer, on the 
surface epithelial cells.
1  H. pylori infection causes gastric 
mucosal inflammation, which could not only lead to 
chronic gastritis and peptic ulcer disease, but also to gas-
tric adenocarcinoma or low-grade mucosa-associated lym-
phoid tissue (MALT) lymphoma.
1 H. pylori eradication has 
become a widely accepted initial treatment strategy for 
stage I gastric marginal zone B cell lymphoma of MALT. 
Although in 60-80% of these cases, H. pylori-positive low- 
grade B-cell gastric MALT lymphoma regress both endo-
scopically and histopathologically after H. pylori eradica-
tion,
2,3 both the factors that might be predictive of the re-
sponse to the eradication therapy, as well as the optimal 
duration of observation needed prior to the potential start 
of additional second-line treatment in the non-responsive 
cases remain controversial.
LITERATURE REVIEW FOR GASTRIC MALT 
LYMPHOMA
  A literature search was performed in PubMed using the 
keywords [gastric MALT lymphoma] and [H. pylori] for 
the publications during the last 5 years (2004-2008). 
After accumulating the list of included studies, pub-
lications not related to either gastric MALT lymphoma or 
H. pylori were excluded. In addition, the recent develop-
ments in the molecular mechanisms involved in the 
pathogenesis of gastric MALT lymphomas were reviewed.82   Gut and Liver, Vol. 3, No. 2, June 2009
Fig. 1. (A) Endoscopy images of a low-grade MALT lymphoma lesion at the upper gastric corpus mucosa in a 46-year-old female 
patient obtained 1 month after H. pylori eradication, showing a nodular lesion whose surface contains patchy red spots on a 
discolored background. (B) Endoscopy image of the regressed low-grade MALT lymphoma lesion at the upper gastric corpus mucosa
obtained 22 months after H. pylori eradication. (C) Histopathology image (H&E stain) of a low-grade MALT lymphoma lesion at the
upper gastric corpus mucosa 1 month after H. pylori eradication. Small lymphoma cells infiltrated the gastric glands to form 
lymphoepithelial lesions (×20 objective lens). (D) Histopathology image (H&E stain) of the regressed low-grade MALT lymphoma
lesion at the upper gastric corpus mucosa obtained 22 months after H. pylori eradication. Lymphoma cells had disappeared, with 
only partial mononuclear cell infiltrates remaining (×20 objective lens).
Table 1. Complete Remission (CR) Rates after H. pylori 
Eradication in Patients with Low-grade MALT Lymphomas
CR Median  follow  up 
Authors n
(%) (months)
Martinelli  et al.
18
 26 46.0  33.0
de Mascarel et al.
6
 60 46.7  10.0 
Fischbach  et al.
16
 90 62.0  44.6 
Todorovic  et al.
8
 34 64.7  60.0 
Nakamura  et al.
9
 86 65.1  42.2 
Nakamura  et al.
12
 73 75.0  37.0 
Wündisch  et al.
14
120 80.0 75.0 
Chen  et al.
15
 30 80.0  10.0 
Hong  et al.
13
 90 94.4  45.0 
MALT, mucosa-associated lymphoid tissue.
  The initial search yielded 21 manuscripts. Among these, 
6 articles (1 review article, 3 articles dealing with non- 
gastric MALT lymphomas, and 2 articles not dealing with 
H. pylori) were excluded, while the remaining 15 were 
carefully reviewed. Among the 15 articles reviewed, 4 ar-
ticles
4-7 dealt with the diagnosis and the remaining 11 
dealt with the treatment of gastric MALT lymphomas. 
Among the 11 articles dealing with the treatment, 9 ar-
ticles
8-16 reported on H. pylori eradication, 1 article
17 re-
ported reconsideration of surgical treatment after a me-
dian follow-up of 11.5 years after gastrectomy, and 1 ar-
ticle
18 showed significant efficacy of rituximab.Suzuki H, et al: Helicobacter pylori and Gastric MALT Lymphoma   83
1.  Helicobacter pylori eradication
  H. pylori eradication therapy was followed by complete 
remission (CR) of low-grade gastric MALT lymphoma in 
46-94% of the patients (Table 1).
6,8,9,12-16,18  Representative 
upper gastrointestinal (GI) endoscopic images of a 46- 
year-old female patient are shown in Fig. 1. Significant 
regression of the nodular and reddish colored low-grade 
MALT lymphoma lesion observed in the upper gastric 
corpus mucosa (Fig. 1A, one month after the H. pylori 
eradication) was noted at 22 months after the H. pylori 
eradication therapy (Fig. 1B). Histologically, characteristic 
lymphoepithelial lesion (LEL) identified in the upper gas-
tric corpus one month after the eradication (Fig. 1C) dis-
appeared 22 months after the H. pylori eradication (Fig. 
1D).
  Gastric lymphomas are usually staged by endoscopic ul-
trasonography, according to the modified Ann Arbor stag-
ing system by Musshoff and Radaszkiewicz et al.
19 Here, 
“E” means primary extranodal site. Stage E-I means the 
localized involvement of one or more GI sites on one side 
of the diaphragm without lymph node infiltration. Stage 
E-I is further characterized as E-I1 (lymphoma confined to 
mucosa and submucosa) or as E-I2 (lymphoma extending 
beyond submucosa). Stage E-II means the localized in-
volvement of one or more GI sites on one side of the dia-
phragm with lymph node infiltration (any depth of lym-
phoma infiltration into the gut wall). Stage E-II is further 
characterized as E-II1 (Infiltration of regional lymph no-
des) or as E-II2 (Infiltration of lymph nodes beyond re-
gional area). Then, stage E-III means the localized in-
volvement of the GI tract and/or lymph nodes on both 
sides of the diaphragm and stage E-IV means the lo-
calized GI bulk of lymphoma with or without infiltration 
of associated involvement of non-GI tract organs or 
tissues.
  According to a prospective multicenter study conducted 
in Germany and Austria by Fischbach et al.
16 o n  9 5  p a -
tients with newly diagnosed MALT lymphoma, the long- 
term outcome (median follow-up; 45 months) after H. py-
lori eradication was characterized by CR in 56 patients 
(62%), minimal residual disease (MRD) in 17 patients 
(18%), and partial remission (PR) in 11 patients (12%). 
In this study, the regression rate was higher in patients 
with stage E-I1 disease as compared with that in those 
with stage E-I2 disease, as diagnosed by endoscopic ultra-
sonography (EUS).
16 Wündisch et al.
14 also reported the 
long-term outcomes of 120 patients with gastric MALT 
lymphoma (stage E-I) after H. pylori eradication; they re-
ported a CR of 80% and a relapse rate of only 3%. In 
their study,
14 both t(11;18)(q21;q21) translocation and 
ongoing B-cell monoclonality were associated with a sig-
nificantly higher risk of no response or relapse, but they 
were also encountered in patients showing CR. In 2006, 
Hong  et al.
13 reported a high CR rate (94%) of gastric 
low-grade MALT lymphoma after H. pylori eradication, 
with a median interval to CR of 3 months. 
  Patients with minimally persisting lymphoma infiltrates 
after successful H. pylori eradication are considered as 
treatment failures and referred for further treatment. 
However, according to the report by Fischbach et al.
10, 
most patients with minimal histological residuals after 
successful eradication had a favorable disease course with-
out anti-cancer treatment, suggesting that a watch-and- 
wait strategy with regular follow up endoscopies and bi-
opsies may be safe and preferred approach in the manage-
ment of these patients.
  In Taiwan,
15 two multicenter prospective studies of H. 
pylori eradication for early-stage gastric lymphoma, one 
for low-grade MALT lymphoma, and one for high-grade 
transformed tumors (diffuse large B-cell lymphoma 
[DLBCL] with features of MALT), were directly compared. 
In this study, H. pylori was successfully eradicated in 97% 
of  H. pylori-positive low-grade lymphoma patients and 
92% of H. pylori-positive high-grade lymphoma patients, 
resulting in CR in 80% and 64% of the patients in the 
two groups, respectively. After a median follow-up of 
more than 5 years of the complete responders, tumor re-
currence was observed in 13% of the patients with low- 
grade tumors, but none of the patients with the high- 
grade tumors, suggesting that anti-H. pylori therapy is 
considered as one of the treatment options even for ear-
ly-stage  H. pylori-positive gastric DLBCL.
15
  Todorovic et al.
8 reported that in patients of primary 
gastric MALT lymphoma with a median follow-up dura-
tion of 5 years, the CR was 65% (22/34) and PR was 
27% (9/34) after H. pylori eradication, and that the pre-
dictive factors for overall survival were the international 
prognostic index (IPI) score, blood hemoglobin level, er-
ythrocyte sedimentation rate (ESR), and platelet count. 
Nakamura  et al.
9 reported that patients with gastric 
MALT lymphomas responsive to H. pylori eradication ther-
apy had a good prognosis (CR rate: 65%, 56/86), and 
that in non-responders to the eradication, second-line 
treatments resulted in CR. However, especially in the 
case of non-responders to H. pylori eradication therapy 
who decline second-line treatment, careful follow-up is 
necessary to detect development of gastric adenocarcinoma 
and disease progression.
  Helicobacter heilmannii is also known as another bacterial 
pathogen associated with the development of gastritis and 
gastric MALT lymphoma.
20,21 According to the report by 84   Gut and Liver, Vol. 3, No. 2, June 2009
Joo  et al.
11, although H. heilmannii-associated gastritis is 
uncommon and milder than H. pylori-associated gastritis, 
the association may be worthy of note with respect to the 
development of MALT lymphoma.
  In regard to H. pylori-negative cases, according to the 
report by Nakamura et al.
12, although H. pylori-negative 
g a s t r i c  M A L T  l y m p h o m a  i s  c h a r a c t e r i z e d  b y  a  h i g h  f r e -
quency of t(11;18)(q21;q21)
22 and may require additional 
strategies other than antibiotics, 2 of 7 (29%) H. pylo-
ri-negative patients also responded to antibiotic treat-
ment.
  Gastric MALT lymphomas with the API2-MALT1  fusion 
is generally known as resistant to H. pylori eradication 
therapy. A recent study demonstrated the clinical activity 
of the monoclonal antibody to CD20, rituximab in gastric 
MALT lymphoma patients with the API2/MALT1 fusion.
18 
In their study,
18 46% of the patients showed pathological 
and clinical CR, and 31% showed a partial response, with 
only two patients presenting with relapse at 26 and 14 
months after weekly rituximab treatment, respectively. 
This finding suggests that the t(11;18)(q21;q21) trans-
location may not, after all, be a predictive marker of re-
sponse or of subsequent relapse following rituximab 
therapy.
18
  On the other hand, some gastric MALT lymphomas 
that are negative for the API2-MALT1 fusion may show 
resistance to H. pylori eradication therapy. These tumors 
have not been well-characterized and the precise clin-
icopathological features are still unknown. Further studies 
regarding other chromosomal translocations and other 
bacterial infections that might be involved in the patho-
genesis of gastric MALT lymphomas are necessary.
2. Chromosomal translocations in gastric MALT 
lymphoma (Table 2)
    As mentioned above, gastric MALT lymphomas are 
characterized not only by regression in response to H. py-
lori eradication therapy,
3 but also by chromosomal 
translocations.
23 The API2-MALT1 fusion that results from 
chromosome translocation t(11;18)(q21;q21) has been re-
ported to be a predictor of non-responsiveness to H. pylori 
eradication therapy.
22 It has been suggested that since 
API2-MALT1 fusion transcripts might promote survival of 
the MALT lymphomas by producing inhibition of apopto-
sis, they help in the survival of MALT lymphomas.
24,25
  On the other hand, t(1;14)(p22;q32) occurs in 1-2% of 
MALT lymphomas and has been detected in the stomach, 
salivary glands, intestines, and lungs.
26 The BCL10  gene 
was isolated from the breakpoint of the t(1;14) trans-
location, with deregulated expression of BCL10 in the 
MALT lymphomas.
27,28 BCL10 activates nuclear factor 
kappa B (NF-kB), a transcription factor for several surviv-
al-related genes, via interaction with a MALT1 gene 
product.
29 Moreover, recent studies have shown that the 
API2-MALT1 fusion protein activates NF-kB and is asso-
ciated with nuclear BCL10 expression.
29,30 Thus, some 
chromosomal translocations involving the API2-MALT1 fu-
sion promoting  tumor cell survival and deregulation of 
BCL10  activating several survival genes have been re-
p o r t e d  i n  M A L T  l y m p h o m a s . 
3. Gene expression profiles of gastric MALT lym-
phomas (Table 2)
  Recent studies using microarray analyses have revealed 
the gene expression profiles of gastric MALT lymphomas. 
Mueller  et al.
20 reported increased expression of genes 
previously to be associated with malignancies, including 
laminin receptor-1 and MDR-1, in LELs, and increased ex-
pression of calgranulin A/Mrp-8 in destructive LELs and 
malignant lymphomas. Thus, they suggest that the gene 
expression profiles only represent the histopathological 
stages of MALT lymphomas. Huynh et al.
31 also reported 
the gene expression signatures in gastric MALT lympho-
mas. Several surface markers of hematopoietic cells, such 
as CD1c, CD40, CD44, CD53, CD83, CD86 and members 
of the HLA-D family, were found to be upregulated in 
MALT lymphomas. Since MALT lymphomas typically ex-
hibit the following immunophenotype-CD19(＋), CD20(＋), 
CD21(＋), CD79a(＋), CD5(−), CD10(−), CD23(−), and 
cyclin D1(−), the gene expression profile does not simply 
reflect a higher B-cell component, but also the anti-
gen-dependent survival of the lymphoma cells.
    MicroRNAs (miRNAs) are small non-coding RNAs 
that can downregulate various target genes, including tu-
mor- associated genes. Recent studies have demonstrated 
that aberrant expression of miRNAs plays critical roles in 
the development of human malignancies.
32 Lu et al.
33 
have reported that miRNA expression profiles can be 
used to classify the developmental lineages and differ-
entiation stages of tumors. Interestingly, miRNA ex-
pression profiles are more accurate for tumor classi-
fication than conventional mRNA profiles. We recently 
demonstrated overexpression of hematopoietic-specific 
miRNAs and oncogenic miRNAs in gastric MALT lym-
phomas with the API2-MALT1 fusion, and proposed that 
the miRNA expression profiles could be novel bio-
markers and therapeutic targets for gastric MALT 
lymphomas.
34,35
4. Aberrant DNA methylation in gastric MALT lym-
phomas (Table 2)
  Since epigenetic alterations, such as DNA methylation, Suzuki H, et al: Helicobacter pylori and Gastric MALT Lymphoma   85
Table 2. Molecular Alterations in Gastric MALT Lymphomas
Molecular events Alterations in gastric MALT lymphoma References
Chromosomal translocations t(11;18)(q21;q21); API2-MALT1 fusion 22, 24, 25
t(1;14)(p22;q32); deregulated expression of BCL10 26, 27, 28
Alterations in gene expression  Increased expression of laminin receptor-1, MDR-1,  20
 and calgranulin A/Mrp-8
Increased expression of CD1c, CD40, CD44, CD53, CD83,  31
  CD86,  and members of the HLA-D family
Overexpression of hematopoietic-specific miRNAs and  34, 35
 oncogenic miRNAs
Epigenetic alterations Aberrant DNA methylation of p16/INK4a 36
Aberrant DNA methylation of p16/INK4a  and  p57/KIP2 37
Aberrant DNA methylation of p15, p16, p73, hMLH1,  38
  DAPK, MINT1, MINT2, and  MINT31
MALT, mucosa-associated lymphoid tissue.
are known to be involved in the initiation and develop-
ment of human malignancies, determination of the DNA 
methylation status might be a powerful tool for the diag-
nosis and treatment of malignancies. 
  Methylation of the p16/INK4a gene was observed in 
60% of MALT lymphomas, however, the p16  gene meth-
ylation status was not correlated with the presence of 
API2-MALT1 fusion or any other clinicopathological fac-
tors, suggesting that aberrant methylation of the p16 gene 
might be an early event in MALT lymphomagenesis.
36 
Min  et al.
37 also demonstrated methylation of p16/INK4a 
and  p57/KIP2  in 41.7 and 29.2%, respectively, of 
low-grade MALT lymphomas, respectively. Determination 
of the methylation profiles of 8 CpG islands, including 
p15, p16, p73, hMLH1, DAPK, MINT1, MINT2, and 
MINT31, revealed that H. pylori-dependent MALT lympho-
mas showed more than 4 methylated genes, while non H. 
pylori-dependent cases showed less than 2 methylated 
genes, indicating that H. pylori-dependent and non H. pylo-
ri-dependent gastric MALT lymphomas may have a differ-
ent pathogenesis, including the aberrant DNA methyl-
ation pattern.
38
  Thus, aberrant DNA methylation plays critical roles in 
the pathogenesis of gastric MALT lymphomas and de-
tection of the DNA methylation pattern may hold prom-
ise as a clinical tool for surveillance of gastric MALT 
lymphomas. 
SUMMARY
    Although numerous reports have suggested a good 
prognosis of gastric low-grade MALT lymphomas after H. 
pylori eradication, for cases not responsive to antibiotic 
therapy, further molecular characterization is necessary to 
establish the most suitable therapeutic strategy, including 
additional second-line treatment or a watch and wait 
policy. Molecular events associated with gastric MALT 
lymphomas such as chromosomal translocations, altered 
gene expressions and epigenetic modifications (Table 2) 
might provide predictive information for therapeutic re-
sponsiveness as well as for recurrence or relapse of the 
disease. Large-scale cohort studies with molecular exami-
nations should be performed to establish the therapeutic 
strategies for gastric MALT lymphomas after the success-
ful  H. pylori eradication.
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